Your local clinical lab



Understanding Occult Blood Test

The fecal occult blood test (FOBT), aka Stool Hemoglobin or Stool Blood, is a fecal immunochemical test (FIT) that qualitatively detects human hemoglobin from blood in fecal samples. It is often referred to as FIT.

This is a useful screening aid for detecting primarily lower gastrointestinal (G.I.) disorders that may be related to iron deficiency anemia, diverticulitis, ulcerative colitis, polyps, adenomas, colorectal cancers or other G.I. lesions that can bleed. It is recommended for use by health professionals as part of routine physical examinations and in screening for colorectal cancer or other sources of lower G.I. bleeding.

Colorectal cancer is… Continue reading

Colorectal Cancer: FIT Twice a Year After 50

Recent research data published in the September issue of Clinical Gastroenterology and Hepatology confirms that an annual or biennial fecal immunological test (FIT) beginning at age 50 years in combination with a single colonoscopy at age 66 years is as effective as current colorectal cancer (CRC) screening guidelines. Moreover, the hybrid screening strategy requires fewer resources than the current CRC screening protocol. The findings are consistent with a recent US Preventive Services Task Force analysis.
The authors compared the hybrid screening strategy with single-modality screening using annual FIT, sigmoidoscopy every 5 years, and colonoscopy every 10 years. They also… Continue reading

Coffee May Help Prevent Breast Cancer

cup-of-coffee-for-cancerDrinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug Tamoxifen, a study at Lund University in Sweden has found.

Patients who took the pill, along with two or more cups of coffee daily, reported less than half the rate of cancer recurrence, compared with their Tamoxifen-taking counterparts who drank one cup or less.

The team followed over 600 breast cancer patients from southern Sweden for an average of five years. Approximately 300 took Tamoxifen. The drug, a common hormone therapy after breast cancer surgery, reduces the risk of new tumours by blocking… Continue reading